AstraZeneca's Calquence Steps Into Blood Cancer Ring With Mighty Imbruvica
AstraZeneca's launch of BTK inhibitor Calquence (acalabrutinib) in mantle cell lymphoma will mark the company's market entry in liquid tumors, up against a formidable competitor – J&J/Abbvie's first-in-class Imbruvica.
You may also be interested in...
AZ is counting on Calquence’s safety profile to gain ground against AbbVie/J&J’s blockbuster BTK inhibitor Imbruvica.
The results move AstraZeneca closer to challenging AbbVie and Johnson & Johnson’s blockbuster Imbruvica in the blood cancer market.
AstraZeneca’s Calquence, Pfizer’s Lorbrena and Lilly’s Verzenio, which all address unmet medical needs, have been endorsed by an expert panel in India, paving the way for their potential introduction on the market. But all eyes will be on pricing to ensure access in this largely self-pay market.